Solodyn Generic Pay-for-Delay Class Action Settlement

Medicis Pharmaceutical Corp. and Impax Laboratories have agreed to pay a total of $43 million to end a class action lawsuit alleging they violated state antitrust and consumer protection laws and unjust enrichment laws by agreeing not to compete with other drug companies, keeping lower-cost generic versions of Solodyn off the market.

Lead plaintiffs, including health insurers and consumers, alleged in several class action lawsuits that a cheaper, generic version of the acne medicine, Solodyn, was kept off the market as a part of a conspiracy by drug companies to keep the costs of the drug high. The class action lawsuits were eventually consolidated into multidistrict litigation (MDL).

Medicis and Impax do not admit any liability under the terms of the class action settlement, but agreed to pay two Classes – a consumer and third-party payor Class – along with attorney fees and costs and incentive awards.

Consumer Class Members include those who purchased Solodyn between July 23, 2009 and Feb. 25, 2018 and reside in certain states.

Third-Party Payor Class Members include all health insurance companies, third-party administrators, health maintenance organizations, health and welfare plans that make payments from their own funds, and other health benefit providers and entities with self-funded plans that contract with a health insurer or administrator to administer their prescription drug benefits who purchased Solodyn between July 23, 2009 and Feb. 25, 2018 in certain states.

The deadline to object to the Medicis settlement is May 28, 2018. Those Class Members who want to object to the Impax settlement have until June 18, 2018 to do so.

Who’s Eligible

There are two categories of Class Members, the Consumer Class and Third-Party Payor Class.

Class Members include those who purchased, paid and/or provided reimbursement for some or all of 45mg, 55mg, 65mg, 80mg, 90mg, 105mg, 115mg, and/or 135mg Solodyn and/or its generic equivalent prescription in Alabama, Alaska, Arizona, Arkansas, California, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming, the District of Columbia and Puerto Rico from July 23, 2009 and Feb. 25, 2018.

Potential Award

“At this time, it is unknown how much each member of the Class who submits a valid claim will receive. Payments will be based on a number of factors, including the number of valid claims filed by all members of the Class and the dollar value of each member of the Class’ purchase(s) in proportion to the total claims filed.”

Proof of Purchase

No proof of purchase necessary; however, the settlement administrator may ask for additional proof of payment.

Claim Form

CLICK HERE TO FILE A CLAIM »

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

7/31/2018

Case Name

In re: Solodyn (Minocycline Hydrochloride) Antitrust Litigation, Case No. 1:14-md-02503, in the U.S. District Court for the District of Massachusetts

Final Hearing

7/11/2018 (Medicis)

7/18/2018 (Impax)

UPDATE: The Solodyn Generic Pay-for-Delay Class Action Settlement was granted final approval on July 18, 2018.  Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page.

UPDATE 2: On September 19, 2019, a Motion to Distribute Settlement Funds was filed with the court. This motion has not yet been granted. Top Class Actions will let our viewers know when the motion is approved. Any comments containing personal claim information will be deleted to protect viewer privacy.

UPDATE 3: On October 11, 2019, the Motion to Distribute Settlement Funds in the Solodyn Generic Pay-for-Delay Class Action Settlement was granted by the court. It is not known how quickly claims will be paid.  Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page.

UPDATE 4: On Jan. 6, 2020, Top Class Actions viewers started receiving checks worth as much as $1,575.64 from the Solodyn generic delay class action settlement. Congratulations to everyone who filed a claim and got PAID!

Settlement Website

www.SolodynCase.com

Claims Administrator

In re: Solodyn Antitrust Litigation (End-Payor Action)
c/o A.B. Data Ltd.
P.O. Box 173034
Milwaukee, WI 53217
800-332-7414
info@SolodynCase.com

Class Counsel

Michael M. Buchman
MOTLEY RICE LLC

Steve Shadowen
HILLIARD & SHADOWEN LLP

Defense Counsel

Counsel for Impax:
Steven C. Sunshine
Tara L. Reinhart
Julia K. York
Sean M. Tepe
SKADDEN ARPS SLATE MEAGHER & FLOM LLP

Counsel for Medicis:
J. Douglas Baldridge
Lisa Jose Fales
Danielle R. Foley
VENABLE LLP